Frank Yocca's Insider Trades & SAST Disclosures
Frank Yocca's most recent trade in BioXcel Therapeutics Inc was a trade of 34 Restricted Stock Units done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Frank Yocca.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 387 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 1,873 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 229 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 1,839 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 5,064 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 29,361 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 28,799 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 2,606 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.35 per share. | 14 Dec 2024 | 225 | 28,931 (0%) | 0% | 0.4 | 79 | Common Stock |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 205 | 29,156 (0%) | 0% | 0.4 | 73 | Common Stock |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 21,250 | 35,453 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 17 Sep 2024 | 7,175 | 28,278 (0%) | 0% | 0.5 | 3,946 | Common Stock |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 5,625 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 14,558 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 13,995 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 3,127 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 14 Sep 2024 | 355 | 14,203 (0%) | 0% | 0.7 | 245 | Common Stock |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 1,875 | 1,875 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 13,846 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 6,188 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 13,284 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 3,648 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 14 Jun 2024 | 372 | 13,474 (0%) | 0% | 1.3 | 476 | Common Stock |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 6,750 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 13,830 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.64 per share. | 14 Mar 2024 | 1,067 | 12,763 (0%) | 0% | 2.6 | 2,812 | Common Stock |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 4,169 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 11,580 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Yocca D. Frank | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 4,690 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | D. Frank Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 11,059 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 5,211 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 10,538 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 10,017 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 5,732 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 6,253 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 10,481 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 14 Mar 2023 | 985 | 9,496 (0%) | 0% | 19.7 | 19,396 | Common Stock |
| BioXcel Therapeutics Inc | Frank D. Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 20 Jan 2023 | 50,000 | 8,397 (0%) | 0% | 30 | 1,500,000 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 33,350 | 33,350 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 8,337 | 8,337 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 48.47 per share. | 15 Mar 2021 | 14,370 | 59,027 (0%) | 0% | 48.5 | 696,514 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 49.30 per share. | 15 Mar 2021 | 630 | 58,397 (0%) | 0% | 49.3 | 31,059 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 56.49 per share. | 16 Feb 2021 | 6,805 | 80,292 (0%) | 0% | 56.5 | 384,414 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 58.54 per share. | 16 Feb 2021 | 2,886 | 76,269 (0%) | 0% | 58.5 | 168,946 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.43 per share. | 16 Feb 2021 | 1,772 | 73,997 (0%) | 0% | 60.4 | 107,082 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.88 per share. | 16 Feb 2021 | 1,300 | 87,097 (0%) | 0% | 55.9 | 72,644 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 57.71 per share. | 16 Feb 2021 | 1,137 | 79,155 (0%) | 0% | 57.7 | 65,616 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 61.20 per share. | 16 Feb 2021 | 600 | 73,397 (0%) | 0% | 61.2 | 36,720 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 59.46 per share. | 16 Feb 2021 | 500 | 75,769 (0%) | 0% | 59.5 | 29,730 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 15,000 | 54,310 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.41 per share. | 25 Jan 2021 | 15,000 | 103,397 (0%) | 0% | 0.4 | 6,150 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 48.39 per share. | 25 Jan 2021 | 6,521 | 92,504 (0%) | 0% | 48.4 | 315,551 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 49.35 per share. | 25 Jan 2021 | 4,107 | 88,397 (0%) | 0% | 49.3 | 202,680 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.62 per share. | 25 Jan 2021 | 3,472 | 99,025 (0%) | 0% | 47.6 | 165,337 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 46.94 per share. | 25 Jan 2021 | 900 | 102,497 (0%) | 0% | 46.9 | 42,246 | Common Stock |
| BioXcel Therapeutics Inc | Frank Yocca | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 45,000 | 45,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges